AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [06/08/2026 13:20 PDT] AbCellera Biologics Inc. (NASDAQ:ABCL), Down By 100% ($6.37) From $6.37 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [06/05/2026 08:02 PDT] ABCL Expected to Trade Down After Bearish Patterns Develop
• [06/04/2026 08:09 PDT] ABCL Expected to Trade Down After Bearish Patterns Develop
• [06/03/2026 08:16 PDT] ABCL SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [05/15/2026 10:29 PDT] AbCellera Biologics Inc. (NASDAQ:ABCL), Down By 100% ($4.77) From $4.77 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [05/14/2026 07:05 PDT] ABCL Expected to Trade Down After Bearish Patterns Develop
• [05/11/2026 10:29 PDT] AbCellera Biologics Inc. (NASDAQ:ABCL), Up By 100% ($4.82) From $4.82 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/08/2026 07:10 PDT] ABCL Expected to Trade Up After Bullish Patterns Develop
• [05/04/2026 10:29 PDT] AbCellera Biologics Inc. (NASDAQ:ABCL), Up By 100% ($3.99) From $3.99 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [04/22/2026 03:26 PDT] ABCL Expected to Trade Up Short Term
• [04/17/2026 10:30 PDT] AbCellera Biologics Inc. (NASDAQ:ABCL), Up By 100% ($3.49) From $3.49 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions